Evidence map›Paper›PMID 31729408›Full record

ArticleScientific reports2019

Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer.

So Mee Kwon, Anuradha Budhu, Hyun Goo Woo, Jittiporn Chaisaingmongkol, Hien Dang, Marshonna Forgues, Curtis C Harris, Gao Zhang, Noam Auslander, Eytan Ruppin and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

So Mee KwonLaboratory of Human Carcinogenesis and Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, USA.
Anuradha BudhuLaboratory of Human Carcinogenesis and Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, USA.
Hyun Goo WooLaboratory of Human Carcinogenesis and Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, USA.ORCID http://orcid.org/0000-0002-0916-893X
Jittiporn ChaisaingmongkolLaboratory of Human Carcinogenesis and Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, USA.ORCID http://orcid.org/0000-0001-8019-5562
Hien DangLaboratory of Human Carcinogenesis and Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, USA.
Marshonna ForguesLaboratory of Human Carcinogenesis and Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, USA.
Curtis C HarrisLaboratory of Human Carcinogenesis and Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, USA.
Gao ZhangMolecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, PA, 19104, USA.
Noam AuslanderCancer Data Science Lab, National Cancer Institute, National Institute of health, MD, 20892, USA.
Eytan RuppinCancer Data Science Lab, National Cancer Institute, National Institute of health, MD, 20892, USA.
Chulabhorn MahidolLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Mathuros RuchirawatLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok, 10210, Thailand.ORCID http://orcid.org/0000-0001-6402-2442
Xin Wei WangLaboratory of Human Carcinogenesis and Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, USA. xw3u@nih.gov.ORCID http://orcid.org/0000-0001-9735-606X
National Cancer Institute · USChulabhorn Research Institute · THThe Wistar Institute · US

Funding

Molecular signatures for liver cancer diagnosis and treatment stratificationZ01BC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 1999 to 2008
$1.8M
The role of cancer stem cells in liver cancer heterogeneity and subtypesZ01BC010876 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN · 2008 to 2008
$490k
The identification of human hepatocellular carcinoma metastasis genesZ01BC010877 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN · 2008 to 2008
$327k
Intramural NIH HHS Z01 BC010313Intramural NIH HHS Z01 BC010876Intramural NIH HHS Z01 BC010877
6 · The paper itself

Abstract

Chronic inflammation and chromosome aneuploidy are major traits of primary liver cancer (PLC), which represent the second most common cause of cancer-related death worldwide. Increased cancer fitness and aggressiveness of PLC may be achieved by enhancing tumoral genomic complexity that alters tumor biology. Here, we developed a scoring method, namely functional genomic complexity (FGC), to determine the degree of molecular heterogeneity among 580 liver tumors with diverse ethnicities and etiologies by assessing integrated genomic and transcriptomic data. We found that tumors with higher FGC scores are associated with chromosome instability and TP53 mutations, and a worse prognosis, while tumors with lower FGC scores have elevated infiltrating lymphocytes and a better prognosis. These results indicate that FGC scores may serve as a surrogate to define genomic heterogeneity of PLC linked to chromosomal instability and evasion of immune surveillance. Our findings demonstrate an ability to define genomic heterogeneity and corresponding tumor biology of liver cancer based only on bulk genomic and transcriptomic data. Our data also provide a rationale for applying this approach to survey liver tumor immunity and to stratify patients for immune-based therapy.

Indexed as

Genetic HeterogeneityGenomicsChromosomal InstabilityComputational BiologyDisease ProgressionFemaleGene Expression ProfilingHumansImmunotherapyLiver NeoplasmsLymphocytes, Tumor-InfiltratingMaleMutationNeoplasm GradingNeoplasm StagingSequence Analysis, DNATumor Suppressor Protein p53

Identifiers

PMID31729408
PMCPMC6858353
OpenAlexW2984908854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.